. The observation of hyperactivation of immune cells 1 in a disease that is characterized by immune deficiency captured the essence of the aberrant immune activation that has come to define HIV-induced immunopathogenesis, not only related to B cells but also to other components of the immune system. Over the course of its history, HIVassociated disease has been the subject of intense research and debate, in particular regarding the underlying causes of progressive CD4 + T-cell depletion and loss of immune function (Timeline) . One prevailing hypothesis is that in most untreated individuals, HIV infection leads to chronic immune activation through mechanisms that are largely related to the systemic indirect effects (generally referred to as bystander effects) of ongoing HIV replication 4, 5 . Such bystander effects have been described for CD4 + and CD8 + T cells, as well as for natural killer (NK) cells and B cells. This Review focuses mainly on the B-cell dysregulation that arises during HIV infection and describes how changes in B-cell physiology and function are affected by the suppression of plasma viraemia through combination antiretroviral therapy (ART). Recent interest in refocusing efforts on antibody-based HIV vaccines provides a timely opportunity to review our current understanding of the mechanisms of B-cell pathogenesis in HIVassociated disease. Although a comprehensive analysis of the antibody response to HIV is beyond the scope of this Review, salient features of B-cell responses against HIV in infected individuals are discussed in BOX 1 and potential reasons to explain the poorly effective antibody responses against the virus are listed in As with many other areas of the immunopathogenesis of HIV-associated disease, insights into B-cell dysfunction have progressed rapidly since the availability of combination ART, which has been extremely effective in decreasing HIV viraemia to below detectable levels in a high percentage of properly treated individuals. Before the era of effective ART, B-cell hyperactivation and poorly inducible antibody responses were widely reported in HIV-infected individuals 1, [6] [7] [8] [9] . Since the introduction of effective combination ART in the mid 1990s, it has become possible to delineate the immune defects associated with HIV infection that are related to ongoing viral replication as opposed to the defects that remain despite the suppression of detectable viraemia. In addition, combination ART has allowed us to examine more clearly the potential mechanisms of immune dysfunction and immunopathogenesis in individuals who are infected with HIV.
The scope of HIV-induced B-cell defects can be best appreciated by first considering the various human B-cell subpopulations that circulate in the peripheral blood, from which most observations of HIV-induced defects have been made. In healthy individuals, most B cells in the peripheral blood are either resting naive B cells or memory B cells that express either switched or unswitched antibody isotypes (IgG, IgE and IgA, or IgM and IgD, respectively). In HIV-infected individuals, several additional B-cell subpopulations (which are not normally present to any substantial degree in the peripheral blood of uninfected individuals) can make up considerable fractions of the total B-cell population in the peripheral blood. These include immature transitional B cells, exhausted B cells, activated mature B cells and plasmablasts (FiG. 1) . As discussed in this Review, many of the B-cell defects that have been described in HIVassociated disease can be attributed to the expansion or contraction of one or several of these B-cell subpopulations. Such alterations, together with the immune evasion mechanisms of the virus, help to explain the deficiencies in antibody responses against HIV and other pathogens in HIV-infected individuals.
Direct effects of HIV viraemia on B cells
HIV infection results in persistent viral replication, leading to variable levels of detectable plasma viraemia in most individuals who do not receive effective ART. The effects of ongoing HIV replication on B cells are thought to reflect a combination of direct interactions of B cells with the virus, as discussed in this section, and indirect interactions that are associated with a wide range of systemic alterations, which are discussed in the following section.
Direct interactions between HIV and B cells were first reported several years ago 10 , although there is little evidence that HIV can productively replicate in B cells in vivo. There is, however, strong evidence that HIV binds to B cells in vivo through interactions between the complement receptor CD21 (also known as CR2), which is expressed on most mature B cells, and complement proteins bound to HIV virions that are circulating in vivo 11, 12 ( FiG. 2) . Such immune-complex-based interactions might provide stimulatory signals to B cells, although the low frequency of B cells directly interacting with HIV virions would predict that this is a minor activating pathway 12 . It is more probable that through this interaction, B cells facilitate cell-to-cell transmission of HIV 13 . A similar mechanism of HIV interaction has been suggested for follicular dendritic cells (FDCs) 14 , which also express CD21 and might function as a long-lived extracellular reservoir for HIV even in the presence of effective ART 15 .
Additional potential HIV-binding receptors have been identified on B cells, including DC-specific ICAM3-grabbing non-integrin (DC-SIGN), other C-type lectin receptors 16, 17 and surface immunoglobulins of the variable heavy chain 3 (V H 3) family 18 . Although evidence from in vitro models 16, 17 and from analyses of V H 3-family immunoglobulin-expressing B cells 18 suggests that these interactions directly mediate the effects of HIV on B cells, direct in vivo evidence for such effects is lacking. Furthermore, the low frequency of B cells carrying HIV virions on their cell surface compared with the magnitude of B-cell dysregulation in HIV-viraemic individuals indicates that other indirect mechanisms of B-cell immunopathogenesis exist (FiG. 2) . In this regard, similar arguments have been made for CD4 + T cells, as the frequency of infected CD4 + T cells is insufficient to account for their progressive loss and dysfunction 4 .
Indirect effects of HIV viraemia on B cells
HIV-induced B-cell hyperactivity. HIV-induced immune-cell activation is one of the few widely accepted hallmarks of HIV pathogenesis and disease progression. The hyperactivation of B cells by HIV is characterized by several features: hypergammaglobulinaemia 1,19-21 ; increased polyclonal B-cell activation 1, 19, 22 ; increased cell turnover 23, 24 ; increased expression of activation markers, including CD70, CD71 (also known as TFRC), CD80 and CD86 (reFs [25] [26] [27] [28] ; an increase in the differentiation of B cells to plasmablasts as measured by phenotypical (FiG. 1) , functional and morphological measures 19, 23, 29, 30 ; increased production of autoantibodies 22, 31, 32 ; and an increase in the frequency of B-cell malignancies 33 . Role of complement in HIV trapping by immune cells 11, 12 Role of IL-10 in hypergammaglobulinaemia 37 ART decreases B-cell activation 63 Nef as indirect source of B-cell activation 42 Increased B-cell turnover 24 Association of IL-7 with CD4 + T-cell lymphopenia 46, 47 CD21 low B cells and hypergammaglobulinaemia 19 Exhausted T cells identified 54, 55 Impaired IgM + memory B cells 92 IFN identified as a pathogenic factor 34 Exhausted B cells identified 52 HIV mimicry and tolerance of B cells 31 Irreversible loss of memory B-cell response 94 LPS as a mediator of systemic B-cell activation 39 Increased immature transitional B cells 49 • HIV binds C-type lectins on B cells 16 The factors that contribute to HIV-viraemiainduced immune-cell hyperactivation in vivo remain largely unknown, but are a matter of intense research and debate. Several cytokines and growth factors have been suggested to directly or indirectly trigger the activation of B cells in HIV-viraemic individuals, including interferon-α (IFNα) 34 , tumour necrosis factor (TNF) 35 , interleukin-6 (Il-6) 36 , Il-10 (reF. 37 ), CD40 ligand 37 and B-cell-activating factor (BAFF; also known as TNFSF13B) 17 (FiG. 2) . Many of these factors are thought to be associated with B-cell hyperactivation in HIV-viraemic individuals because of their increased serum levels during HIV infection. In the case of IFNα, plasmacytoid DCs (pDCs) might be responsible for increased production in chronically HIV-viraemic individuals 34, 38 . Bacterial lipopolysaccharide (lpS), possibly released into the circulation following intestinal tissue damage owing to large-scale HIV-induced T-cell depletion in the gut, has also been proposed to activate B cells 39 . However, the mechanism of activation is probably indirect, possibly through the induction of pro-inflammatory cytokines such as TNF and IFNα 40 , because human B cells do not express lpS receptors 41 . In addition, HIV proteins, including gp120 (reFs 17, 35) and Nef 42, 43 , have been proposed to act as direct or indirect activators of B cells through mechanisms that remain mostly speculative. In the case of gp120, its binding to C-type lectins that are expressed on B cells has been shown to induce immunoglobulin class switching and increased expression of the immunoglobulin class-switching enzyme activation-induced cytidine deaminase 17 . In the case of Nef, the effects on B cells might be divergent. On the one hand, Nef has been shown to accumulate in B cells and to inhibit immunoglobulin class switching by interfering with CD40-ligand-mediated signalling 44 . On the other hand, Nef can indirectly promote polyclonal B-cell activation and increase CD4 + T-cell permissiveness to infection with HIV by inducing macrophages to secrete pro-inflammatory cytokines 42 (FiG. 2) . However, these initial studies were largely based on in vitro observations, and further investigation is required to determine their in vivo relevance. In this regard, the polyclonal B-cell-activating properties of Nef were recently correlated with HIV-induced B-cell alterations in infected individuals 43 . Specifically, HIV-infected macrophages were shown to secrete the acute phase protein ferritin through a Nef-dependent mechanism, and direct correlations were found between the extent of hypergammaglobulinaemia, levels of ferritin in the plasma and HIV viral load. As is discussed in detail below, there is also growing evidence to suggest that IFNα and type I IFN-stimulated genes (ISGs) might have a role in the HIV-viraemia-induced immune-cell hyperactivation 23, 34, 45 .
Box 1 | B-cell responses against HIV
An effective antibody response against HIV is likely to be thwarted by the numerous B-cell abnormalities that arise during HIV-associated disease. In addition, impediments to HIV-specific antibody responses that relate to the virus itself probably contribute to the defect (TABle 1) . It is currently unclear which, if any, of these antibody-related factors contribute to the lack of control of HIV replication, and conflicting results from B-cell-depleting experiments in SIV infection have not clarified whether antibodies can restrict virus replication 113, 114 . It is also unclear whether fully functional B cells can restrict the virus in spite of the antibody escape and other evasion mechanisms of HIV. As several reports have shown, the antibody response to HIV following infection is clearly ineffective, with the early response being largely directed against non-neutralizing epitopes of the HIV envelope and later B-cell responses lagging behind a rapidly diversifying virus 115, 116 . In addition, the HIV-specific IgA response at mucosal sites, where HIV transmission mainly occurs and where HIV preferentially replicates 40 , is low when compared with other classes of immunoglobulin 117, 118 . Although there is no clear explanation for the paucity of HIV-specific IgA responses during HIV infection, the early destruction of organized lymphoid tissues in the intestinal mucosa and the inhibition of class switching by the HIV protein Nef have been proposed as potential reasons 44 . Furthermore, there is renewed interest in exploring the innate immune responses to HIV infection as a way of preventing systemic dissemination of the virus while the adaptive arm of the immune response is generated 119 . In terms of humoral immunity, the innate immune response mainly consists of natural antibodies that are produced by marginal zone B cells 120 . If the suggestion that IgM + memory B cells in the peripheral blood are related to marginal zone B cells in the spleen is correct (see main text), then this presents another impediment to mounting a successful innate immune response to HIV given the recently described defects of IgM + memory B cells in HIV-infected individuals 83, 89, 92 . 
T-cell lymphocytopenia
A disorder of unknown cause that is characterized by decreased CD4 + T-cell counts in the absence of evidence for HiV-1 or HiV-2 infection or any known immunodeficiency or therapy associated with decreased levels of CD4 + T cells.
Taken together, these studies have identified several potential modulators of B-cell hyperactivation that are induced by ongoing HIV replication. In addition, B cells activated by HIV viraemia can themselves potentiate immune activation of other cells, either by cell-cell interactions (which are favoured by the increased expression of co-stimulatory molecules such as CD80 and CD86 by B cells) [25] [26] [27] [28] or by secreting pro-inflammatory cytokines such as Il-6 and TNF 35 .
HIV-induced lymphopenia. In most untreated individuals, HIV infection leads to the progressive loss of CD4 + T cells. Several years ago, expression of the T-cell homeo static cytokine Il-7 was shown to be dysregulated in HIV-infected individuals with advancing HIV-associated disease; increased serum levels of Il-7 were linked to decreased numbers of CD4 + T cells 46, 47 . Although Il-7 is not absolutely essential for human B-cell development, it can induce the proliferation of human B-cell precursors 48 . Indeed, we have shown that high serum levels of Il-7 directly correlated with increased frequencies of immature transitional B cells in the peripheral blood of HIV-infected individuals (FiG. 1) . These, in turn, directly correlated with HIV plasma viraemia and inversely correlated with CD4 + T-cell numbers 49 . High viral load and low CD4 + T-cell counts are thus associated with increased serum levels of Il-7 and increased numbers of immature transitional B cells (FiG. 2) . A similar association between increased serum levels of Il-7, B-cell immaturity and decreased CD4 + T-cell counts was observed in patients with non-HIV-related idiopathic CD4 + T-cell lymphocytopenia (ICl), which suggests that HIV-induced CD4 + T-cell lymphopenia (and not HIV viraemia itself) drives the expansion of immature transitional B cells in HIVinfected individuals 50 . So, as first reported several years ago 27 , there is evidence of an increase both in B-cell activation and in the frequency of immature B cells in HIV-infected individuals.
HIV-associated B-cell exhaustion. The loss of CD21 expression on peripheral blood B cells is a reliable marker of ongoing HIV replication and disease progression 51 . CD21 low B cells constitute a heterogeneous population of cells in HIV-infected individuals (FiG. 1) ; one fraction of the CD21 low B-cell compartment is made up of CD27 + B cells that have undergone HIV-induced activation and differentiation to plasmablasts 19 and another fraction is made up of immature transitional CD10 + B cells that are over-represented as a result of HIV-induced T-cell lymphopenia 49 . However, a large proportion of CD21 low B cells in HIV-viraemic individuals does not fit into either of these fractions, and we now believe that these B cells constitute an exhausted B-cell subpopulation 52 ( FiG. 3) . The term exhaustion -which was first used to describe T cells in the rodent model of lymphocytic Short-lived plasmablasts choriomeningitis virus infection 53 and later in HIV infection in humans 54,55 -refers to virus-specific immune cells that have lost function because of the chronic nature of the viral infection. phenotypically, these cells express high levels of inhibitory receptors such as programmed cell death 1 (pD1) and cytotoxic T-lymphocyte antigen 4 (CTlA4) [54] [55] [56] . The discovery of a subpopulation of memory B cells in human tonsils 57 that expresses the putative inhibitory receptor Fc-receptor-like 4 (FCRl4), high levels of CD20, low levels of CD21 and the classic marker of B-cell memory, CD27, provided us with a starting point to characterize the previously unidentified CD21 low B cells that are present in the peripheral blood of HIV-viraemic individuals, which we reasoned might be related to this . Of note, the tonsil-tissue-derived memory B cells were defined by the expression of FCRl4 and were not necessarily negative for CD21 and CD27 (reFs 57,58), whereas their counterparts in the peripheral blood of HIV-viraemic individuals were more precisely defined as CD21 low CD27 -; accordingly, we named them tissue-like memory B cells 52 . FCRl4 was not the only putative inhibitory receptor that was associated with these tissue-like memory B cells in peripheral blood. High levels of many B-cell inhibitory receptors, including CD22, CD72, leukocyte-associated immunoglobulin-like receptor 1, CD85j (also known as lIlRB1 and IlT2) and CD85k (also known as lIlRB4 and IlT3), were expressed by tissue-like memory B cells from HIV-viraemic individuals 52 . A similar increase in the expression of many inhibitory receptors is a signature feature of persistent-virus-induced T-cell exhaustion, which provides further indication that tissue-like memory B cells could be an exhausted B-cell counterpart 59 . • In addition to the expression of inhibitory receptors, tissue-like memory B cells and virus-exhausted T cells have similar alterations in their expression of homing receptors and adhesion molecules. Specifically, tissue-like memory B cells upregulate their expression of CXC-chemokine receptor 3 (CXCR3) and CD11c, which are required for migration to sites of inflammation, and downregulate their expression of CC-chemokine receptor 7 (CCR7) and CD62l, which are required for migration to lymph nodes 52, 59 . Tissuelike memory B cells also express decreased levels of CXCR4 and CXCR5, two chemokine receptors that are crucial for B-cell trafficking to germinal centres, where the maturation of T-cell-dependent B-cell responses occurs 60 . The decreased surface expression of CXCR5 by B cells from HIV-viraemic individuals might be due to ligand-mediated internalization of CXCR5 resulting from overexpression of its ligand, CXC-chemokine ligand 13 (CXCl13), as measured in the serum 61 . Virus-specific T-cell exhaustion is characterized by functional defects that are manifested by the incremental loss of proliferative and effector properties 62 [54] [55] [56] 59 . Taken together, there is strong evidence suggesting that tissue-like memory B cells are an exhausted B-cell subpopulation in the peripheral blood of HIV-viraemic individuals (FiG. 3) . As HIV-specific responses are enriched in B cells that show signs of functional exhaustion, such dysregulation might contribute to the inefficiency of the antibody response against HIV in infected individuals. So, chronic HIV viraemia is associated with the expansion of several aberrant B-cell subpopulations, including immature transitional, hyperactivated and exhausted B cells, which collectively are likely to contribute to various facets of B-cell dysfunction.
Impact of effective ART on B-cell abnormalities
The mechanisms of B-cell and generalized immune dysfunction in HIV-infected individuals were difficult to address before the availability of effective ART. The effective decrease of HIV viraemia by ART has not only led to substantial reductions in the morbidity and mortality of individuals infected with HIV, but has also provided opportunities to investigate the causes of HIVinduced immune dysfunction. Since 1996, when combination ART was first used widely in the developed world to effectively suppress HIV viraemia, it has become clear that many of the B-cell abnormalities that are associated with HIV-replication-induced immune-cell activation can be reversed by ART, whereas some deficiencies, particularly in memory B cells, persist even after several years of effective ART.
B-cell defects that are reversed by ART.
One of the first studies to address the effects of decreasing HIV viraemia by ART on B-cell responses showed a reversal of several B-cell abnormalities in both acutely and chronically infected individuals after treatment 63 . The B-cell abnormalities that were decreased by ART included hypergammaglobulinaemia and HIV-specific and HIV-non-specific B-cell responses, as measured by the number of B cells that spontaneously secrete high levels of immunoglobulins. Several studies have since confirmed and extended these findings 19, 20, [64] [65] [66] [67] . The increased frequency of B cells secreting high levels of immunoglobulins during viraemia was attributed to the expansion of the CD21 low B-cell subpopulation in the peripheral blood of HIV-viraemic individuals 19 . plasmacytoid morphology and low proliferative potential, both of which are features of B-cell differentiation to plasmablasts, were observed in the CD21 low , but not the CD21 hi , B-cell fraction of HIV-viraemic individuals. Decreased proliferation of B cells in response to various B-cell stimuli during HIV viraemia has been described in numerous studies and is largely attributed to the over-representation of the aberrant B-cell subpopulations that are associated with ongoing HIV replication (described above) 68, 69 . Finally, the increased expression of CD38, B-cell maturation antigen (BCMA) and CD27 on CD21 low B cells, which are additional features of terminal B-cell differentiation, was associated with HIV viraemia in genotypic and phenotypic analyses 23 . Thus, several B-cell manifestations of HIV infection in untreated individuals are reversed by effective ART.
B cells of HIV-viraemic individuals also express high levels of activation markers, including CD70, CD71, CD80 and CD86 (reFs [25] [26] [27] [28] . Several studies have shown that the expression of these activation markers is normalized by the ART-mediated decrease in HIV plasma viraemia 23, 25 . HIV-induced B-cell activation in vivo has been shown to result in impaired function ex vivo, as measured either by the B-cell response to specific stimuli or by the ability of B cells to provide co-stimulatory signals to CD4 + T cells 25, 30, 70 . These findings indicate that HIV-induced hyperactivation of B cells inhibits their capacity to engage in effective cognate B-cell-T-cell interactions following encounter with antigen, a defect that could be exacerbated by Nef-induced inhibitory effects on the CD40 signalling pathway 44 . One of the consequences of HIV-induced chronic immune-cell activation is increased cell turnoverthat is, an increase in both proliferation and cell death. Several in vivo studies have shown increased turnover of CD4 + and CD8 + T cells, as well as of NK cells and B cells, during viraemic HIV and simian immunodeficiency virus (SIV) infections compared with the rate of cell turnover in the absence of infection; this increased turnover is reversed by ART 24, 71 . In addition, expression of the cell cycle marker Ki-67 is increased in B cells from HIV-viraemic individuals compared with HIV-aviraemic and HIV-negative individuals 23 , and most of this increase in Ki-67 expression is by CD21 low plasmablasts 52 (FiG. 1) . Furthermore, during nonpathogenic SIV infection in natural hosts, in which high viraemia persists in the absence of CD4 + T-cell depletion and progression to AIDS 72 , the turnover of B cells and other lymphocytes is similar to that of uninfected animals 73 . These differences between pathogenic and non-pathogenic SIV infection indicate that immune-cell activation, as reflected by increased cell turnover, is a key feature of HIV pathogenesis 72 . In more recent comparisons between pathogenic and non-pathogenic SIV infections, a direct link was proposed between chronic immune-cell activation that is induced during pathogenic SIV infection and the expression of IFNα and ISGs 34 . By comparing several components of the innate immune response, this study showed that the absence of pathogenesis was associated with a low cell turnover and muted responses of pDCs, which are the main producers of IFNα. low pDC responses have also been reported in another non-pathogenic SIV setting 38 . Several ISGs that are upregulated in B cells (and other lymphocyte populations) of HIV-viraemic individuals compared with HIV-aviraemic and HIV-negative individuals have been identified 23 , indicating that HIV viraemia is associated with the general induction of ISGs (reviewed in reF. 45 ). The data from pathogenic and non-pathogenic SIV infections suggest that during pathogenic HIV infection and ongoing viral replication, chronic immune-cell activation (of B cells and other immune cells) might be related to the ability of the virus to induce pDCs to secrete high and sustained levels of IFNα, although further studies are required to clarify this issue.
During chronic immune-cell activation induced by ongoing HIV replication, both cell proliferation and cell death are increased, with the net effect determining, at least in part, whether the total number of cells increases or decreases over time 4 . During the clinically asymptomatic phase of HIV infection, ongoing viral replication causes progressive CD4 + T-cell depletion, whereas the number of CD8 + T cells remains increased. In most HIV-infected individuals, the initiation of ART leads to a gradual increase in CD4 + T-cell counts and a decrease in CD8 + T-cell counts 74 . Although less is known about the effects of HIV infection on B-cell numbers, several studies have shown that B-cell numbers are decreased in HIV-infected individuals 21, [75] [76] [77] . Furthermore, following ART, B-cell numbers increase and B-cell dynamics in response to infection and ART are more closely related to those of CD4 + rather than CD8 + T cells 76, 78 . Although the redistribution of cells from tissues to peripheral blood might contribute to changes in B-and T-cell numbers before and after ART 79 , there are also many indications that an increased rate of B-cell death during ongoing viral replication contributes to a net loss of B cells 23, 80, 81 . In this regard, several genes that are involved in the extrinsic apoptotic pathway are among the ISGs that are induced by HIV viraemia 45, 82 . One such ISG encodes the death receptor CD95 (also known as FAS), the expression of which is increased by B cells from HIV-viraemic individuals [83] [84] [85] and is largely confined to the expanded CD21 low B-cell subpopulation 23 . The increased expression of CD95 has been associated with increased susceptibility of B cells to CD95-mediated apoptosis 80 , which in turn directly correlates with HIV viraemia 23, 81 ( FiG. 2) . Decreased B-cell survival in HIV-viraemic individuals has also been attributed to additional factors. These include the decreased responsiveness of B cells to the B-cell survival factor BAFF as a result of decreased expression of the BAFF receptor on CD21 low B cells 23 and the over-representation of immature transitional B cells, which are highly susceptible to intrinsic apoptosis as a result of decreased expression of pro-survival members of the B-cell lymphoma 2 family 81 . The increase in B-cell numbers with ART is accompanied by a decrease in the frequency and number of B cells that are prone to cell death, including activated mature CD21 low B cells and immature transitional B cells 76 , thereby providing an explanation for why HIV viraemia is associated with a net loss of B cells.
In summary, the effects of ART on B cells are mainly attributed to the decrease in HIV viraemia, which leads to an overall decrease in B-cell turnover, hyperactivation and apoptosis. In addition, the increase in CD4 + T-cell counts following the reduction in HIV viraemia by ART is associated with a decrease in the frequency of immature transitional B cells.
IgM + memory B cell
An unswitched CD27 + memory B cell circulating in the peripheral blood that might be related to marginal zone B cells.
Marginal zone B cell
A mature B cell that is enriched anatomically in the marginal zone of the spleen, which is the interface between red pulp and white pulp.
Systemic lupus erythematosus
An autoimmune disease that is characterized by the potential for multiorgan involvement and production of antibodies that are specific for components of the cell nucleus.
Common variable immunodeficiency
A primary immunodeficiency disease with a heterogeneous cause and phenotype that is characterized by hypogammaglobulinaemia. (FiG. 1) , a marker that is often used to define memory B cells. Memory B cells are mostly regarded as longlived, resting, antigen-experienced cells that are rapidly inducible after exposure to cognate antigen 88 . Based on this definition, studies have shown that although ART leads to decreased numbers of CD27 + activated B cells and plasmablasts 29, 76 , the increase in the number of CD27 + resting memory B cells following treatment occurs slowly and remains incomplete 76, 85, [89] [90] [91] . Numerous studies have shown that memory B-cell responses and serological memory against both T-celldependent and T-cell-independent antigens are decreased in HIV-infected individuals 26, [92] [93] [94] [95] . However, few studies have addressed the effect of decreasing HIV viraemia by ART on these responses. Initial findings from individuals who had received ART for a short time suggested that memory B-cell responses could be restored by ART 96 . By contrast, most of the more recent studies indicate that restoration of memory B-cell responses by ART is either absent or incomplete [92] [93] [94] . In many of the experiments, the B-cell responses that were measured were specific for T-cell-dependent antigens from influenza virus, measles virus and tetanus toxoid; in these cases, the persistence in the loss of CD4 + T-cell help could explain the lack of restoration of B-cell memory responses following the administration of ART. However, decreased memory B-cell responses against the polysaccharide pneumococcal vaccine 92, 94 , which is a T-cell-independent immunogen, indicate that HIV infection is also associated with intrinsic B-cell memory defects, and loss of responsiveness to pneumococcus was not reversed by ART. Recent findings indicate that this loss in memory function is associated with a decreased frequency of igm + memory B cells 92 , a phenotype that is also seen in splenectomized individuals, who are also more susceptible to pneumococcal infection 97 . Given the proposed role of spleen-derived marginal zone B cells in responding to bacterial antigens 63, 83, 94 . Suggestions that the early initiation of ART might reverse immune defects remain anecdotal, although early initiation of ART does seem to reverse one defect of chronic HIV infection, the low frequency of IgM + memory B cells 83 . whether the restoration of normal numbers of IgM + memory B cells translates into an improved responsiveness to T-cell-independent immunogens remains to be determined, as does the broader issue regarding the impact of early initiation of ART on the preservation of the immune system.
B-cell defects in other diseases
Advances in defining and characterizing the numerous B-cell subpopulations in humans are providing new insights into human immunology and new opportunities to understand the mechanisms of B-cell pathogenesis in various diseases that are characterized by immune dysfunction. During the delineation of B-cell dysfunctions in HIV, it became apparent that some of these abnormalities had been reported in other diseases in the absence of HIV infection. Common B-cell deficiencies are found across a broad range of infectious and non-infectious diseases of known and unknown origin. Although the complexities of each disease and the heterogeneity of any given condition can limit the number of clear associations, certain common pathways are worth considering (TABle 2) .
Immature transitional B cells. Immature transitional B cells in the peripheral blood were first described as a transient subpopulation following bone marrow transplantation 100 and were then shown to be an expanded population in the peripheral blood of patients with systemic lupus erythematosus (SlE) 101 . The expansion of immature transitional B-cell populations has also been reported in several settings of immunodeficiency, including advancing HIV disease, common variable immunodeficiency and ICl 49, 50, 92, 102 . Furthermore, immature transitional B cells can persist for several years at the expense of memory B cells in a subset of patients with SlE who were treated with the B-cell-depleting antibody rituximab 103 . whether the clonal expansion and sustained high frequency of immature transitional B cells in various disease settings reflect a common driving factor in these diseases is not clear, although the presence of immature transitional B cells in these diseases is frequently associated with depleted memory B cells (TABle 2) . It is conceivable that immature transitional B cells arise from homeostatic pressures that are induced by lymphopenia and/or from conditions that increase the expression levels of early B-cell stimulatory factors such as BAFF and Il-7 (reFs 49, 50, 104) . The consequences of increased numbers of immature transitional B cells in the peripheral blood are also not well understood, but further investigation is warranted given that this stage of development is characterized by high autoreactivity 105 , which is another manifestation of many diseases of B-cell dysregulation (TABle 2) .
Activated B cells.
The presence of plasmablasts in the peripheral blood of HIV-viraemic individuals is probably a consequence of HIV-induced immune-cell activation. Increased numbers of plasmablasts in the peripheral blood have also been reported in several other diseases that induce B-cell hyperactivity, including other infectious diseases, autoimmune diseases and primary immunodeficiencies [106] [107] [108] [109] [110] (TABle 2) . Furthermore, several of the same genes are upregulated in B cells from HIV-viraemic individuals and individuals suffering from SlE; these include genes that are associated with the terminal differentiation of B cells and type I IFNs 23, 108 . Most recently, the identification of subpopulations of CD27 -memory B cells in healthy human tonsils and in the peripheral blood of individuals with various conditions that are characterized by B-cell dysregulation (TABle 2) indicates that certain microenvironments and inflammatory conditions can give rise to unique memory B-cell subpopulations that do not express the classic markers of B-cell memory 52, 57, 61, 111 . A more comprehensive analysis of the properties of these cells could provide important insights into B-cell responses and B-cell dysregulation in various disease settings. Other open questions with potential implications for B cells include whether immune-modulating agents can reverse the defects that are induced by chronic HIV disease and whether therapies aimed at decreasing immune-cell activation can help to prevent the loss of immune function. In this regard, recent findings from a pathogenic SIV infection model indicate that in vivo treatment with antibodies that block the inhibitory receptor pD1 can improve B-cell responses 112 . whether similar effects can be expected in humans is uncertain given the low level of expression of pD1 on B cells of HIV-infected individuals (S. M., unpublished observations). Further investigation is required to compare all aspects of B-cell dysregulation during HIV and SIV infection to more clearly define how the pathogenic mechanisms of B cells relate in these two settings. Nonetheless, such considerations have implications not only for preserving immune responses against secondary pathogens but also for preserving or boosting HIVspecific immune responses, including antibody responses. Finally, given the pivotal role of B cells in many human diseases and the number of similarities in B-cell defects observed across these diseases, the search for common pathways of pathogenesis should lead to a better understanding of the underlying causes of B-cell defects and to therapies that can reverse these defects. 
Concluding remarks

